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Background: Obstructive sleep apnea (OSA) is associated with increased risk for cardiovascular morbidity and
mortality. Epidemiological and animal models studies generate hypotheses for innovative strategies in OSA
management by interfering intermediates mechanisms associated with cardiovascular complications. We have thus
initiated the Epigenetics modification in Obstructive Sleep Apnea (EPIOSA) study (ClinicalTrials.gov identifier:
NCT02131610).
Methods/design: EPIOSA is a prospective cohort study aiming to recruit 350 participants of caucasian ethnicity and
free of other chronic or inflammatory diseases: 300 patients with prevalent OSA and 50 non-OSA subjects. All of
them will be follow-up for at least 5 years. Recruitment and study visits are performed in single University-based
sleep clinic using standard operating procedures. At baseline and at each one year follow-up examination, patients
are subjected to a core phenotyping protocol. This includes a standardized questionnaire and physical examination
to determine incident comorbidities and health resources utilization, with a primary focus on cardiovascular events.
Confirmatory outcomes information is requested from patient records and the regional Department of Health
Services. Every year, OSA status will be assessed by full sleep study and blood samples will be obtained for
immediate standard biochemistry, hematology, inflammatory cytokines and cytometry analysis. For biobanking,
aliquots of serum, plasma, urine, mRNA and DNA are also obtained. Bilateral carotid echography will be performed
to assess subclinical atherosclerosis and atherosclerosis progression. OSA patients are treated according with
national guidelines.
Discussion: EPIOSA will enable the prospective evaluation of inflammatory and epigenetics mechanism involved in
cardiovascular complication of treated and non-treated patients with OSA compared with non OSA subjects.
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Obstructive sleep apnea (OSA) is the most common re-
spiratory sleep disorder characterized by recurrent epi-
sodes of partial or complete pharyngeal obstruction [1].
Though obesity is the main risk to develop OSA, cranio-
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unless otherwise stated.also important in OSA pathogenesis. Collapse of the upper
airway during sleep leads to recurrent arousals, intermit-
tent hypoxia, and surges in sympathetic activity. These
intermediate mechanics may explain to some extent, the
increased risk of mortality [2], incident hypertension [3,4],
coronary artery disease [5] and stroke [6] described in
OSA. In this context, circulating biomarkers of inflamma-
tion and oxidative stress have been described to be elevated
in some OSA patients, and lowered with CPAP therapy re-
gardless of weight changes [7]. A cause-effect relationship
has been suggested between this systemic inflammatorytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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inflammatory processes in the vessel wall [8]. Such pro-
cesses are considered to be critical determinants of patho-
logical alterations of the vasculature such as thickening of
vessel wall, fatty streak formation, or promotion of athero-
sclerotic plaques. Furthermore, raised levels of proinflam-
matory cytokines involved in the atherosclerotic process,
such as Interleukin-6 (IL-6) and C-reactive protein (CRP),
have been reported in OSA. Nevertheless, these cytokines
are also increased in obesity [9] and some studies do not
show an independent association between OSA and IL-6
and/or CRP levels [10-12]. Other studies carried in obese
patients with and without OSA, found that untreated
OSA, rather than obesity, is a major determinant of vascu-
lar endothelial dysfunction, inflammation, and elevated
oxidative stress in obese patients [13].
Among patients with OSA, the systemic inflammatory
variability response can be explained by different pattern
of epigenetic modifications induced by the apneic epi-
sodes and consequently altered expression of genes
involved in the atherosclerotic process. Continuous hyp-
oxia can induce hypermethylation of genes involved in
cardiovascular diseases [14,15], but the role of intermit-
tent hypoxia -a characteristic feature of OSA- is not so
well known. However, increased methylation in the pro-
moter region of the FOXP3 gene has been recently
described in children with OSA and systemic inflamma-
tion [16]. The FOXP3 gene controls the differentiation
of lymphocytes into regulatory T lymphocytes (Treg), a
subset of T helper cells that inhibit atherosclerosis by
modulating lipoprotein metabolism [17].
Most OSA patients attending sleep clinics have many
confounding comorbidities, e.g. smoking and alcohol
habits, obesity, dyslipemia, hypertension, etc.…,. These con-
founding variables are also associated with systemic low-
grade inflammation that makes it difficult to determine the
independent role of OSA in the pathogenesis of cardiovas-
cular diseases. Furthermore, the onset of epigenetic changes
in adults with OSA remains unknown. Our hypothesis is
that changes in epigenetic regulation of systemic inflamma-
tion and metabolic dysfunction in OSA, are linked to accel-
erated cardiovascular morbidity. The Epigenetics Status
and Subclinical Atherosclerosis in Obstructive Sleep Apnea
(EPIOSA) study is a 5-yr longitudinal study with the overall
aim to identify epigenetic markers associated to prevalent
and progression of subclinical atherosclerosis in individuals
with OSA, as well as biomarkers that may serve as surro-
gate end-points. The present article describes the purpose
and design of the study.
Methods/Design
Study objective
The EPIOSA study has the following specific aims: 1) Use
of questionnaires, sleep studies, carotid ultrasonographyand cerebral magnetic resonance imaging (MRI) for the
definition of OSA subpopulations and controls among in-
dividuals without comorbidities; 2) Identification and def-
inition of the parameters that predict disease progression
over 5 yrs of follow-up. For the purposes of the present
study, disease progression is defined in terms of changes
in sleep disordered breathing variables, symptoms, carotid
artery intima-media thickness (IMT) and plaque and new
microblebs in MRI; 3) Identification of useful biomarkers
for disease progression by measuring known biomarkers
that correlate with OSA severity, in blood and urine
samples; 4) Identification of novel epigenetic factors
and/or biomarkers correlating with poor outcomes in
OSA and controls. This will be analyzed by cytometry
analysis, DNA methylation in genes subserving inflam-
matory functions RNA transcriptomics; and 5) assess-
ment of the effect of CPAP (Continuous positive airway
pressure) on inflammatory and epigenetic mechanisms
and disease progression.
Study design
EPIOSA is a 5-yr non-interventional longitudinal pro-
spective study being conducted at the Sleep Clinic of
the Hospital Universitario Miguel Servet, a large teach-
ing hospital in Zaragoza (Spain). Following a baseline
visit, subjects are to be followed-up at 3, and then every
year. All subjects will continue to receive their usual care
by their primary physician and sleep specialist through-
out the study. CPAP treatment will be started according
to the Spanish National guidelines, free of cost for the
patients [18].
Subject participation
We have estimated to enroll up to 300 consecutive OSA
male patients aged 20–60 yrs, with baseline apnea-
hipopnea index ≥ 5 events per hour of sleep (AHI). In
addition, we expect to recruit 50 control subjects (AHI < 5)
aged 20–60 yrs and matched by body mass index (BMI).
The inclusion and exclusion criteria for OSA patients and
control subjects are shown in Table 1. All participants will
be advised regarding life-style modification, exercise, diet
and to avoid smoking or alcohol consumption.
Measurements
Clinical data
A questionnaire for data collection was developed. This
included assessment of socio-demographic data, weight,
height, waist, hip and neck circumferences, healthy behav-
iors, daily exercise routines, smoking history, consumption
of alcohol or other toxic habits, previous medical diagno-
sis, presence of comorbidities, personal and family history
of disease, and medication use. Daytime somnolence
is assessed with the Epworth test [19]. Blood pressure is
measured according to international guidelines by certified
Table 1 Selection criteria
Inclusion criteria Exclusion criteria
● Males aged 20 – 60 years ● Any history of cigarette/tobacco
smoking use
● AHI≥ 5 events per hour of sleep
(OSA group) and AHI < 5
(control group)
● Alcohol abuse
● Willingness to participate in the
study and complying with the
study by signing a written
informed consent
● Arterial blood hypertension (arterial
blood pressure: ≥140 mmHg systolic
and/or ≥90 mmHg diastolic or taking
antihypertensive medication)
Low high-density lipoprotein (HDL)
cholesterol (<40 mg/dL) or high
LDL cholesterol (≥130 mg/dL) or
taking lower lipid drugs.
● Available for study visits over
5 years
● Fasting plasma glucose >126 mg/dl
or taking anti diabetic medications
● Other metabolic diseases (e.g.,
hypothyroidism)
● Present or past history of vascular
diseases, including myocardial
infarction, angina, coronary artery
procedures (coronary artery bypass
graft or percutaneous coronary
intervention), aneurysm, transient
ischemic attack or stroke.
● Autoimmune diseases
● Past or present history of malignancies
● Chronic inflammatory diseases
(e.g., Crohn disease)
● Chronic infectious diseases
(e.g., chronic viral hepatitis)
● Chronic respiratory diseases
(e.g., asthma)
● Morbid obesity (body mass index
≥40 kg/m2)
● Any chronic oral therapy
● Sleep disorders other than OSA
● Having undergone upper airway
surgery
● Having previously use CPAP therapy
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Spirometry is performed according to the standard
criteria [21].
Sleep study
At our clinic, full polysomnography is used for patients
believed to suffer from sleep disorders other than or in
addition to sleep apnea, which are not to be included in
the present study. For the rest of the patients with sus-
pected OSA diagnosis, a type 3 portable sleep monitor will
be used. The sleep study includes continuous recording of
airflow from a nasal pressure cannula, thoracic-abdominal
motion, oxygen saturation, snoring and body position. Re-
sults from all sleep studies are analyze using standardcriteria by trained personnel that are blind to the present
protocol. An apnea is defined as an absence of airflow of
10 seconds or longer; a hypopnea as an airflow reduction
(>50%) lasting ≥ 10 seconds with a decrease in oxygen sat-
uration over 4%. Obstructive apneas are defined as the ab-
sence of airflow in the presence of thoracic-abdominal
motion. The AHI is calculated based on the average num-
ber of apnea plus hypopnea episodes per hour of record-
ing time. Optimal titration of CPAP is obtained by using
auto-CPAP (Autoset-T; ResMed, Sydney, Australia), ac-
cording to previous validation procedures by the Spanish
Sleep and Breathing Group [22]. Compliance with CPAP
will be measured using the machines’ internal timers. All
patients will attend a new sleep study every year.
Laboratory analysis
At baseline and every year, whole blood samples are
drawn using a 21G butterfly needle into serum gel, EDTA,
sodium fluoride and PaxgeneW tubes (PreAnalytix GmbH,
Switzerland). Serum glucose, triglycerides, total cholesterol
and HDL cholesterol will be measured by spectropho-
tometry (Chemical Analyzer ILAB 650, Instrumentation
Laboratory), and serum apolipoproteins A and B, will be
measured by kinetic nephelometry (Immunochemistry
Analyzer IMMAGE 800, BeckmanCoulter). Within two
hours after collection, high sensitive C-reactive protein
(CRP) will be measured based on a particle-enhanced tur-
bidimetric immunoassay technique. For biobanking, about
15 ml of EDTA blood and 5 ml of blood without anti-
coagulant for serum preparation are to be fractionated
into plasma, serum and whole blood and in 1 ml dot-
coded metal-free cryotubes are to be stored at −80°C. In-
flammatory markers to be assessed are shown in Table 2.
Flow cytometry
At baseline, whole fresh blood with EDTA will be obtained
for flow cytometry. Table 3 shows the cells stained, and
also the antibodies and kits used. The samples will be in-
cubated for 15 min at room temperature, then acquired in
a GALLIOS flow cytometer (Beckman Coulter) and ana-
lyzed with the KALUZA software (Beckman Coulter).
DNA methylation analysis
Part of the blood samples collected in EDTA tubes are
stored at −80°C until DNA isolation, which is performed in
the Department of Molecular Biology at the Faculty of
Veterinary of the University of Zaragoza. Genomic DNA is
obtained with the use of the illustra blood genomic Prep
Midi Flow Kit (GE Healthcare, UK) following the manufac-
turer’s instructions. Genome-wide DNA methylation pro-
files will be studied in approximately 1 μg of genomic
DNA treated with sodium bisulfite. The converted DNA
will be analyzed using Illumina’s Infinium Human Methyla-
tion 450 BeadChip assay (Illumina, San Diego, CA, USA).
Table 2 Outcome measurements in the Epigenetics in Obstructive Sleep Apnea (EPIOSA) study
Measurement Description Frequency of assessment
Questionnaires, Dietary, Epworth Sleepiness Scale Each visit
Vital signs Including sitting blood pressure, heart rate, height and weight Each visit
Exhaled carbon monoxide Confirmation of smoking status Each visit
Spirometry Post-bronchodilator FVC, FEV1 and FEV1/FVC Baseline
Electrocardiogram 12-lead resting electrocardiogram Baseline
Sleep Study At home type 3 monitor for diagnosis and at home autoCPAP
for CPAP titration (if appropriated)
Baseline and every year
Blood sample Standard biochemistry and lipid markers: Total cholesterol, LDL,
HDL, TG, Apo A, Apo B.
Baseline and last visit
Inflammatory markers: TNF-α, IFN-ϒ, IL-1β, IL-6, IL-8, IL-10.
Urine sample Microalbuminuria, 8-isoprostane Baseline and every year
Carotid Ultrasonography High-resolution B-mode assessment of carotid artery intima-media
thickness and plaque
Baseline and every year
Magnetic resonance imaging Cerebral microbleeds detection Baseline and last visit
Flow cytometry Fresh peripheral blood T-cell phenotype Baseline and last visit
DNA methylation Genome-wide DNA methylation status Baseline and last visit
miRNA microarray analysis Levels of candidate miRNAs regulated by aberrant DNA methylation Baseline and last visit
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randomly distributed. The assay allows determination of
DNA methylation levels at >450,000 CpG sites covering
all designable RefSeq genes, including promoter, 5′, and 3′
regions. It captures CpG islands and shores, non-CpG
methylated sites, microRNA promoter regions and disease-
associated regions identified through genome-wide associ-
ation studies [24]. Illumina array data will be processed
using the Methylation Module of GenomeStudio v1.9 soft-
ware. To identify differentially methylated regions (DMRs),
we will use a 1-kb sliding window and apply Fisher’s
method to combine P values for each 1-kb region on the
basis of all probes within each window [25]. Significant
DMRs will be selected at a 1% FDR on autosomes and 5%
FDR on chrX. After statistical analyses, the methylationTable 3 Subset of T cell population to be analyzed
Antibody-kit Clone







CD 62 L DREG 56
Human regulatory T cell cocktail* CD4: SK3, CD25: 2A3, CD127: HIL-7R-M2
*T reg was defined as CD4+/CD25+/CD127 (low/-) phenotype (ref. [23]).patterns of the gene of interest will be confirmed by se-
quencing of the 24 bisulfite-treated DNA samples used for
the genome wide analysis.
Gene expression analysis
Blood samples stored at −80°C in PaxGene (TM) tubes
will be used for total RNA isolation using PAXgene Blood
RNA Kit (Qiagen, Venlo, Netherlands). Quantitative real
time polymerase chain reactions (qRT-PCR) will be per-
formed to test whether differential methylation patterns of
the selected genes affect their expression level. Comple-
mentary DNA will be synthesized from total RNA using
random hexamers and the SuperScript® III First Strand
Synthesis Kit (Life Technologies, Carlsbad, California,
US). Primers and TaqMan® probes will be selected fromFluorescence Catalog number
CD4: FITC CD8: PE CD3: PERCP 4FI8PEI3PPI-50 T. IMMUNOSTEP
FITC 11CF3-100 T IMMUNOSTEP
APC 14A-100 T IMMUNOSTEP
FITC 15 F-100 T IMMUNOSTEP
PE 16PE2-100 T IMMUNOSTEP
CF BLUE 45CFB2-100 T IMMUNOSTEP
APC 45RAA2-100 T IMMUNOSTEP
APC-eFluor 780 47-0629 eBioscience
1 CD4: fitc, CD 25: PE-Cy7, CD127:
Alexa fluor 647
560249 (BD Pharmigen)
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will be performed in a The StepOne™ Real-Time PCR Sys-
tem (Applied Biosystems, Life Technologies, Carlsbad,
California, US).
MicroRNA analysis
This study is based in the expression of 96 miRNAs. These
miRNAs have been carefully selected based on those pre-
dicted by bioinformatic algorithms and databases to regu-
late genes known to be relevant to inflammation. Total
RNA will be extracted from cryopreserved samples using
Paxgene Blood miRNA kit (PreAnalitiX) according to the
manufacturer’s protocol. RNA integrity will be tested using
the 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
California, US). Samples will be reverse transcribed using
the Taqman®MicroRNA Reverse Transcription Kit (Applied
Biosystems, Life Technologies, Carlsbad, California, US)
and mature miRNAs will be quantified by real-time PCR
using the Taqman®MicroRNA Assays [26]. miRNA expres-
sion will be analyzed using the BioMark 96:96 Dynamic
Array (Fluidigm Corporation, San Francisco, California,
US). Data will be analyzed using the BioMark Real-Time
PCR Analysis Software v2.0 (Fluidigm). The Ct value will
be used for analysis by the 2-ΔΔCt method [27].
Subclinical atherosclerosis imaging
Carotid intima-media thickness (CIMT)
At baseline and every year, CMIT are to be assessed in
all subjects with an ultrasound system (IU22 Philips).
Ultrasound images are acquired by linear high fre-
quency 2-dimensional probes following the protocol of
the Bioimage Study [28]. Carotid plaque is defined as a
focal structure that protrudes into the lumen of the ca-
rotid artery at least 0.5 mm or ≥50% thicker than the
surrounding. Three measurements each are made on
the far wall of the left and right common carotid arter-
ies in end diastole, 1 cm below the point of bifurcation.
The average of the 6 readings will be taken as the
CIMT value.
Magnetic resonance imaging (MRI)
At baseline and after the 5-year follow up, all subjects
are to undergo a cerebral MRI. We use a multisequence
MRI protocol on a 1.5-T scanner (GE Healthcare). For
cerebral microbleeds detection we will use an acceler-
ated three-dimensional T2*-weighted gradient-recalled
echo sequence. MRI scans are viewed by radiology phy-
sicians blinded to the OSA status of the subject. As
previously described cerebral microbleeds are defined as
focal areas of very low signal intensity on T2*-weighted
imaging without signal abnormalities on other struc-
tural sequences [29]. Microbleeds are classified ac-
cording to cerebral localization (lobar brain sites or
infratentorial locations).Power considerations
The calculation of EPIOSA’s planned sample size of 300
patients and 50 matched controls, is based on three esti-
mations: a) in pediatric patients, those with OSA (n = 37),
showed a reduced Treg population and altered Th1:Th2
balance toward Th1 predominance compared with non-
OSA controls (n = 13) [30]; b) differences among DNA
methylation in inflammatory genes were observed among
OSA patients with high hsCRP (n = 31), compared with
normal non-OSA controls (n = 31) [16]; and C) a random-
ized study showed that effective treatment of OSA with
continuous positive airway pressure for 4 months signifi-
cantly decreases IMT as early signs of atherosclerosis in
24 patients with severe OSA [31]. We expected a loss to
follow-up of an average of 2% per year. In this way at the
end of the 5-year follow-up we hope to analyze outcomes
in 270 patients with OSA and 45 without OSA. This sam-
ple size ensures to analyze subgroups of patients accord-
ing with prescribed treatment for OSA. Specifically, the
sample will have 80% power to detect average IMT differ-
ences when comparing OSA patient treated and non-
treated CPAP. The power is calculated based on a 2 SD
with a significance level of 0.0125.
Statistical analyses
Groupwise comparisons (n >2) will be performed using a
nonparametric Kruskal-Wallis test followed by a Mann–
Whitney U test as appropriate. Pairwise comparisons were
performed using a nonparametric Mann–Whitney test
unless otherwise indicated. Chi square tests will be per-
formed for categorical variables. Regression models will be
applied to assess the effect of OSA, biomarkers, peripheral
lymphocytes and epigenetic changes on CIMT, carotid
plaque and cerebral microbleeds. All models will be ad-
justed for age and BMI, and additionally for covariables
that may change the estimated risk beyond 5% Specific
statistics procedures will be performed for the arrays as
described above. STATA-12 for Windows (STATA CORP,
TX, USA) are to be used for all analyses.
Discussion
The Epigenetics Status and Subclinical Atherosclerosis
in Obstructive Sleep Apnea (EPIOSA) study is a clinical
based study of patients with OSA and non-OSA, both
without other associated comorbid conditions. EPIOSA
aims to elucidate mechanisms involved in the develop-
ment of OSA complications with a focus on OSA-
associated subclinical atherosclerosis. To achieve this,
standardized phenotyping of OSA is being performed at
baseline and at one and 5 years, with imaging tech-
niques and biobanking of serum, plasma, DNA, mRNA
and urine. EPIOSA aims to recruit ambulatory patients
attending the Sleep Clinic for study of suspected ob-
structive sleep apnea.
Marin et al. BMC Pulmonary Medicine 2014, 14:114 Page 6 of 8
http://www.biomedcentral.com/1471-2466/14/114Prevalence of OSA is increasing in industrialized coun-
tries. OSA prevalence parallels the “obesity pandemic”.
Both disorders share metabolic and cardiovascular com-
plications that are a major public health and financial
challenge. Obesity is a well known risk factor for cardio-
vascular disorders but the role of OSA as an independent
contributor of cardiovascular outcomes is more contro-
versial since most patients with severe OSA are obese. To
minimized this problem, in this study we will exclude pa-
tients with a BMI > 35 kg/m2.
Atherosclerosis is considered the principal contributor of
cardiovascular disease. Atherosclerotic lesions and athero-
mas are localized in the arterial intima-media layers due to
accumulation of lipids and inflammatory cells. Endothelial
dysfunction triggered by oxidized low-density lipoprotein
(OxLDL) is the first step in atherosclerosis. Endothelial
cells activation results in the expression of adhesion mole-
cules, cytokines and chemokines that attract circulating
monocytes and naïve T lymphocytes. These cells migrate
across the endothelium and infiltrate the vascular wall.
Monocytes then differentiate into macrophages that take
OxLDL to transform in “foam cells”. The accumulation
and activation of T cells recognizing OxLDL in the intima
constitute the adaptive immunity component in the patho-
genesis of atherosclerosis and elicit proinflammatory stim-
uli that further exacerbate and propagate this disease [32].
The importance of adaptive immune activation has been
underlined in the Multi-Ethnic Study of Atherosclerosis
(MESA). In the MESA study, which included otherwise
healthy individuals, higher circulating CD4+ to CD4+ naïve
cells ratio were found to be associated with subclinical ath-
erosclerosis as estimated by carotid ultrasonography [33].
Several subsets of T cells are found within the plaque
mainly of the CD4+ phenotypes including Th1, Th2, Th17
and regulatory T cells (Treg) subtypes. Th1 is the most
abundant T cell in the human plaque and together with
Th17 are considered pro-atherogenic T cells. Th2 cells are
rarely detected in lesions and have been suggested to be
anti-atherogenic. Treg control the Th1/Th2 balance and
are considered to be atheroprotective [34]. Epigenetic regu-
lation is being recognized as an important factor in the
pathogenesis of atherosclerosis. The forkhead box tran-
scription factor, FOXP3, is considered the master switch
in the regulation of Treg development and function [35].
Furthermore, FOXP3+ Tregs inhibit atherosclerosis by
modulating lipoprotein metabolism [17]. A dose-dependent
increase in the methylation of the Treg-specific demethy-
lated region in FOXP3 was observed in cultures of per-
ipheral blood mononuclear cells in patients with acute
coronary syndromes [36], suggesting that epigenetic
suppression of FOXP3 might lead to down-regulation of
Treg cells, and in turn increase the risk of atherosclerosis.
There are many potential mechanisms linking OSA,
endothelial dysfunction, atherosclerosis and cardiovasculardiseases. Sleep loss and fragmentation could trigger endo-
thelial dysfunction and immune response but its remains
to be demonstrated if this occurs in patients with OSA.
Chronic intermittent hypoxia (CHI) is the other hallmark
of OSA. CIH can induce endothelial dysfunction inde-
pendently of respiratory effort in animal models [37]. In
patient with OSA, oxygen desaturation index (ODI), a sur-
rogate of CHI severity has been associated with endothe-
lial dysfunction [38]. On the other hand, ODI emerged
as an independent predictor of carotid and aortic wall
thickness in OSA patients using cardiovascular mag-
netic resonance study [39]. CPAP treatment of OSA
significantly reduces carotid intima-media thickness,
supporting the concept that OSA is an independent risk
factor for atherosclerosis [31]. There is growing evi-
dence that OSA is associated with increased activation
of immune and inflammatory cells including circulating
monocytes, platelets and lymphocytes and proinflam-
matory cytokines such as leukotrienes, interferon-γ,
TNF-α and IL-6 have been reported elevated in OSA
[8]. CRP levels have been particularly studied with con-
flicting results [7,40]. The intermediate process for an
increased risk of atherosclerosis in OSA could be the
presence of this systemic inflammation and immunity
activation as a result of the CHI. There is no evidence of
genetic alterations in patients with OSA that favor the de-
velopment of systemic inflammation, changes the adaptive
immunity or that specifically encourage the emergence of
early atherosclerosis. However, it is likely a different re-
sponse from the pro-inflammatory genes to CIH. This re-
sponse depends in part on epigenetic mechanisms that
promote or suppress the expression of these genes. Re-
cently in pediatric OSA those children with elevated CRP,
were more likely to have increased DNA methylation of
the FOXP3 gene [16]. This result in a reduced Treg popu-
lation and in a swift Th1:Th2 balance towards Th1 pre-
dominance [29]. These immune-inflammatory changes
favor endothelial dysfunction and a pro-atherogenic state
and ultimately an increased risk for cardiovascular dis-
eases. If those mechanisms also play a role in accelerated
atherosclerosis in adults with sleep apnea is unknown. In
conclusion, the current study is novel in several ways: 1) It
is the first study to evaluate the relationship between base-
line OSA phenotypes and normal matched controls with-
out comorbidities and subclinical atherosclerosis and 2) it
will allow prospective analysis of inflammatory bio-
markers, as well as methylation and miRNA abnormalities
in non-OSA subjects and patients with treated or non-
treated OSA. Our results may provide more information
on the association of OSA and cardiovascular diseases and
possibly identifying novel targets for therapeutic interven-
tion. It could also provide evidence that CPAP can not
only improve daytime symptoms, but also have a positive
effect on progression of subclinical atherosclerosis.
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